Docetaxel (NSC-628503) And Vinorelbine (NSC-608210) Plus Filgrastim (NSC-614629) With Weekly Trastuzumab (NSC-688097) For HER-2 Positive, Stage IV Breast Cancer.
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2013
At a glance
- Drugs Trastuzumab (Primary) ; Docetaxel; Filgrastim; Vinorelbine
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 21 Aug 2007 Status change from recruiting to in progress.
- 08 Aug 2005 New trial record.